Premium
Treatment of myasthenia gravis with mycophenolate mofetil: A case report
Author(s) -
Meriggioli Matthew N.,
Rowin Julie
Publication year - 2000
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/1097-4598(200008)23:8<1287::aid-mus22>3.0.co;2-l
Subject(s) - mycophenolate , myasthenia gravis , medicine , prednisone , adverse effect , mycophenolic acid , refractory (planetary science) , immunosuppressive drug , corticosteroid , drug , gastroenterology , pharmacology , transplantation , physics , astrobiology
We report a patient with myasthenia gravis (MG) who had marked clinical benefit in response to treatment with mycophenolate mofetil as documented by serial quantitative measures of strength and muscle fatigue. Our patient had experienced either adverse side effects or a suboptimal response to the usual immunosuppressive agents used in MG. Mycophenolate mofetil was used in combination with cyclosporine and prednisone and allowed for significant reductions in dosage of these immunosuppressants. We conclude that mycophenolate mofetil deserves further study as a therapeutic agent in MG. In particular, its role as a steroid‐sparing agent and as a drug to be used in combination immunotherapy in more severe or refractory cases of MG should be investigated. © 2000 John Wiley & Sons, Inc. Muscle Nerve 23: 1287–1289, 2000.